22/09/2026 Amgen reported positive Phase 3 results for dazodalibep in moderate-to-severe systemic sjögren's disease AbbVie’s RINVOQ® received EU approval for children with active pJIA Amgen reported positive Phase 3 results for dazodalibep in moderate-to-severe systemic sjögren's disease (Ref) Amgen’s Ph3 OASIZ 301 trial of dazodalibep (CD40L antagonist) met its primary endpoint, demonstrating statistically significant and clinically meaningful improvement in systemic disease